The investment, which values Swixx in excess of EUR 1.5 billion, brings in a new strategic partners, SK Capital Partners and Bain Capital Life Sciences, alongside existing shareholders Merieux Partners, HBM Healthcare Investments and Swixx management, who will continue to be involved in the business going forward. The transaction reflects sustained investor appetite for healthcare platforms with strong operational reach across multiple jurisdictions.
With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx BioPharma operates an established platform supporting pharmaceutical and biotechnology companies in accessing markets where direct presence is limited or complex, offering a broad range of services across the product lifecycle.
The NautaDutilh team included Margaretha (Greet) Wilkenhuysen, Hédi Khedache-Thiriet, Max Heuermann, Armin Klüter, and Merlin Amoussou (Corporate and M&A).
